VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

AVEO Oncology and Astellas Pharma Inc. today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC).

29 Sep 2012

Karolinska Institutet scientists discover new approach to treat type II diabetes

An international team of scientists, led from Karolinska Institutet in Sweden, have discovered an entirely new approach to the treatment of type II diabetes. The therapy involves the blockade of signalling by a protein known as VEGF-B and this prevents fat from accumulating in the 'wrong' places, such as in muscles and in the heart. As a result the cells within these tissues are once again able to respond to insulin.

27 Sep 2012

CSL develops new drug candidate against type 2 diabetes

CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease.

27 Sep 2012

LIFR protein suppresses local invasion and metastasis of breast cancer cells

A receptor protein suppresses local invasion and metastasis of breast cancer cells, the most lethal aspect of the disease, according to a research team headed by scientists from The University of Texas MD Anderson Cancer Center.

25 Sep 2012

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Ohr Pharmaceutical today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

24 Sep 2012

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Boehringer Ingelheim is pleased to announce the last patients have been randomised into the Phase III sister trials assessing the efficacy and safety of nintedanib (150 mg twice daily) in patients with idiopathic pulmonary fibrosis (IPF).

24 Sep 2012

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Pfizer Oncology today announced that important data from its lung cancer and renal cell carcinoma (RCC) portfolios will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Vienna, Austria, September 28 - October 2, 2012.

18 Sep 2012

Joslin Diabetes Center, Mass. Eye and Ear partner to form clinical and research alliance

Massachusetts Eye and Ear and the Joslin Diabetes Center announced today that they have reached agreement to form a clinical and research alliance, aimed toward providing coordinated high quality care to eye patients throughout greater Boston, especially those with or at-risk for diabetes-related eye disease.

11 Sep 2012

Combining two drugs may offer new and potent punch against cancer and other diseases

A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal -- such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.

11 Sep 2012

New molecular pathway that leads to preeclampsia identified

Preeclampsia is one of the most dangerous conditions for the expectant mother and the unborn child and is characterized by elevated blood pressure and protein in the urine in the last trimester of pregnancy.

10 Sep 2012

Skin, immune system play an important role in regulating sodium balance and hypertension

High blood pressure is responsible for many cardiovascular diseases that are the leading cause of death in industrialized countries. High salt intake has long been considered a risk factor, but not every type of high blood pressure is associated with high salt intake. This has puzzled scientists for a long time. However, new findings by Professor Jens Titze (Vanderbilt University, Nashville, Tennessee, USA and the University of Erlangen) now point to previously unknown mechanisms.

10 Sep 2012

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

Potential new COPD drug

A study led by researchers at Boston University School of Medicine (BUSM) has shown that a compound used in some skin creams may halt the progression of emphysema and reverse some of the damage caused by the disease. When the compound Gly-His-Lys (GHK) was applied to lung cells from patients with emphysema, normal gene activity in altered cells was restored and damaged aspects of cellular function were repaired.

1 Sep 2012

Disruption of circadian rhythm can inhibit blood vessel growth in the body

Disruptions to the circadian rhythm can affect the growth of blood vessels in the body, thus causing illnesses such as diabetes, obesity, and cancer, according to a new study from Linköping University and Karolinska Institutet in Sweden.

28 Aug 2012

Vision symptoms plus retinal changes trigger need for AMD intervention

An analysis of over 1000 individuals presenting with suspected exudative age-related macular degeneration has revealed which factors are most predictive of the need for treatment.

22 Aug 2012

Molecular Partners, Allergan to develop and commercialize DARPins against ophthalmic diseases

Allergan, Inc. and Molecular Partners AG today announced that they have significantly expanded their existing relationship by entering into two separate agreements to discover, develop, and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases.

21 Aug 2012

Peptide combinations might offer more effective cancer therapy

Two studies suggest that two peptide agents used either together or individually with a low-dose of a standard chemotherapy drug might offer more effective cancer therapy than current standard single-drug treatments.

17 Aug 2012

Ingredient for butter flavor in microwave popcorn is a respiratory hazard

The ingredient 2,3-pentanedione (PD), used to impart the flavor and aroma of butter in microwave popcorn, is a respiratory hazard that can also alter gene expression in the brain of rats. Manufacturers started using PD when another butter flavoring, diacetyl, was found to cause bronchiolitis obliterans, a life-threatening and nonreversible lung disease in workers who inhaled the substance.

13 Aug 2012

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Pfizer Inc. announced that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population.

12 Aug 2012

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech, a member of the Roche Group, today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness

12 Aug 2012

VEGF News and Research

Further Reading

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

Karolinska Institutet scientists discover new approach to treat type II diabetes

CSL develops new drug candidate against type 2 diabetes

LIFR protein suppresses local invasion and metastasis of breast cancer cells

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Joslin Diabetes Center, Mass. Eye and Ear partner to form clinical and research alliance

Combining two drugs may offer new and potent punch against cancer and other diseases

New molecular pathway that leads to preeclampsia identified

Skin, immune system play an important role in regulating sodium balance and hypertension

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Potential new COPD drug

Disruption of circadian rhythm can inhibit blood vessel growth in the body

Vision symptoms plus retinal changes trigger need for AMD intervention

Molecular Partners, Allergan to develop and commercialize DARPins against ophthalmic diseases

Peptide combinations might offer more effective cancer therapy

Ingredient for butter flavor in microwave popcorn is a respiratory hazard

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry focus eBook - The Digital Laboratory (4th edition)

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (3rd Edition)

BFEB: Advances in microplate-based assays and analysis

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation